血浆甲基乙二醛水平与2型糖尿病心血管疾病及死亡相关
研究纳入SMART队列中1003例2型糖尿病患者,基线用质谱法测定血浆甲基乙二醛(MGO)、乙二醛(GO)和3-脱氧葡萄糖酮(3-DG)水平,中位随访8.6年。校正 sex、年龄、吸烟、收缩压、总胆固醇、HbA1c、BMI、既往CVD和用药后,MGO水平升高与总CVD、致死性CVD、全因死亡、心肌梗死和截肢相关,与卒中无明显关联。
要点
- MGO每升高1个标准差,总CVD风险比为1.26(95%CI 1.11-1.42),致死性CVD为1.49(1.30-1.71)。
- MGO与全因死亡(1.25,95%CI 1.11-1.40)、心肌梗死(1.22,1.02-1.45)和截肢(1.36,1.05-1.76)相关。
- MGO与卒中无明显关联(1.03,95%CI 0.79-1.35);3-DG与任何结局均无显著关联。
核心结论
- 血浆MGO和GO水平与2型糖尿病患者的 cardiovascular 死亡相关。
- 作者认为影响二羰基化合物水平可能成为减少2型糖尿病CVD的靶点。
研究设计与样本
- 研究为SMART队列分析,纳入1003例2型糖尿病患者(平均±SD年龄59.1±10.5岁,69.3%男性,61.6%有既往CVD)。
- 基线用质谱法测定血浆MGO、GO和3-DG水平,CVD事件中位随访8.6年。
- 采用Cox回归分析,校正 sex、年龄、吸烟、收缩压、总胆固醇、HbA1c、BMI、既往CVD和用药。
- 风险比按经自然对数转换的二羰基化合物每标准差表示。
主要发现
- 共287人发生至少1次CVD事件(致死性事件194例、心肌梗死146例、卒中72例),346人死亡,60人接受截肢。
- MGO较高与总CVD(HR 1.26,95%CI 1.11-1.42)、致死性CVD(HR 1.49,95%CI 1.30-1.71)、全因死亡(HR 1.25,95%CI 1.11-1.40)、心肌梗死(HR 1.22,95%CI 1.02-1.45)和截肢(HR 1.36,95%CI 1.05-1.76)相关。
- MGO与卒中无明显关联(HR 1.03,95%CI 0.79-1.35)。
- GO较高与致死性CVD显著相关(HR 1.17,95%CI 1.00-1.37),与其他结局无显著关联。
- 3-DG与任何结局均无显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Methylglyoxal (MGO) is a reactive dicarbonyl compound and a potential key player in diabetic cardiovascular disease (CVD). Whether plasma MGO levels are associated with CVD in type 2 diabetes is unknown. RESEARCH DESIGN AND METHODS: We included 1,003 individuals (mean ± SD age 59.1 ± 10.5 years, 69.3% male, and 61.6% with prior CVD) with type 2 diabetes from the Second Manifestations of ARTerial disease cohort (SMART). We measured plasma MGO levels and two other dicarbonyls (glyoxal [GO] and 3-deoxyglucosone [3-DG]) at baseline with mass spectrometry. Median follow-up of CVD events was 8.6 years. Data were analyzed with Cox regression with adjustment for sex, age, smoking, systolic blood pressure, total cholesterol, HbA1c, BMI, prior CVD, and medication use. Hazard ratios are expressed per SD Ln-transformed dicarbonyl. RESULTS: A total of 287 individuals suffered from at least one CVD event (n = 194 fatal events, n = 146 myocardial infarctions, and n = 72 strokes); 346 individuals died, and 60 individuals underwent an amputation. Higher MGO levels were associated with total (hazard ratio 1.26 [95% CI 1.11-1.42]) and fatal (1.49 [1.30-1.71]) CVD and with all-cause mortality (1.25 [1.11-1.40]), myocardial infarction (1.22 [1.02-1.45]), and amputations (1.36 [1.05-1.76]). MGO levels were not apparently associated with stroke (1.03 [0.79-1.35]). Higher GO levels were significantly associated with fatal CVD (1.17 [1.00-1.37]) but not with other outcomes. 3-DG was not significantly associated with any of the outcomes. CONCLUSIONS: Plasma MGO and GO levels are associated with cardiovascular mortality in individuals with type 2 diabetes. Influencing dicaronyl levels may therefore be a target to reduce CVD in type 2 diabetes.
引用
- Hanssen NMJ, Westerink J, Scheijen JLJM, et al. Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes. Diabetes Care. 2018. PMID: 29784769. doi:10.2337/dc18-0159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。